ArticleApoptosis : an international journal on programmed cell death2026
Hesperetin alleviates neuronal pyroptosis by promoting mitophagy via DHCR24/BACE1 signaling pathway after subarachnoid hemorrhage in mice.
Article in Apoptosis : an international journal on programmed cell death, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Pyroptosis is a new type of programmed cell death that plays an important role in neuronal injury after subarachnoid hemorrhage (SAH). The effect of natural compounds in SAH has attracted much attention. Hsperetin has been found to have neuroprotective effects in ischemic stroke, but its role in SAH has not been studied. An in vivo model of SAH in male C57BL/6 mice is constructed by the endovascular perforation method, and the heme intervention HT22 cells simulate the in vitro SAH model. After administration of hesperetin, SAH grade, brain water content (BWC), modified garcia score, neurobehavior tests, cerebral blood flow, transmission electron microscope, western blot, and immunofluorescence staining were conducted. Our study found that hesperetin significantly alleviated neurobehavioral deficits, improved cerebral blood flow, and reduced the expression of NLRP3, GSDMD-N, Caspase-1, ASC, IL-18, which were also demonstrated in vitro. Mechanistically, hesperetin notably promoted mitophagy by regulating DHCR24 and BACE1, thereby inhibiting neuronal pyroptosis. This effect was eliminated by U18666A and 3-MA administration. Our findings demonstrated that hesperetin alleviated neuronal pyroptosis by promoting mitophagy via DHCR24/BACE1 to provide neuroprotective effects on EBI. These results suggest that hesperetin has the potential to be a therapeutic target for SAH.
Indexed as
Identifiers
41518524What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.